Keytruda Qlex, an anticancer drug of Merck (MSD), which is applied with Alteogen's subcutaneous
Merck's (MSD) Keytruda Qlex, using Alteogen's SC tech, hit $830M in Q3 2026 sales, up 79.3% QoQ. It now makes up 9.7% of Keytruda's total sales, growing from 5.5% last quarter. Keytruda's overall Q3 revenue was $8.61B, up 6% YoY. Alteogen may benefit from increased royalties as Keytruda Qlex sales rise.
How this was made
The 30-second read
Why it matters
The sales jump signals rapid adoption of the SC formulation, likely boosting Merck's oncology revenue and royalty income for partner Alteogen.
Market read
First‑time $1 trillion‑won quarterly sales for Keytruda SC could lift Merck's stock and affect biotech sector sentiment.
What to watch
Potential regulatory scrutiny of subcutaneous delivery or competition from other PD‑1 inhibitors could temper upside.
Background
Merck's Keytruda Curex subcutaneous version achieved record quarterly sales, marking a shift from intravenous administration.
Ticker impact
Merck reported Q3 2026 Keytruda Curex sales of $830 million, a 79.3% increase and the first $1 trillion‑won quarter.
likely upward pressure as investors price in strong sales growth and expanding subcutaneous market share
The product posted a 79% quarter‑over‑quarter jump, indicating strong demand and potential for continued royalty revenue for both Merck and Alteogen.
Market effects
Biotech and oncology sectors may see increased investor interest in subcutaneous immunotherapy products.
Korean biotech Alteogen could benefit from royalty upside, supporting Asian biotech sentiment.
Strong sales of a major immunotherapy may influence global pharma competitive dynamics.
Counterpoint
If the sales surge is already priced in, the stock could face a short‑term pullback.
Key entities
- companyMerck & Co.
US‑listed pharmaceutical company reporting Keytruda sales.
- companyAlteogen
Korean biotech providing subcutaneous injection technology.
